The prospective pioglitazone clinical trial in macrovascular events (PROactive'): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients

Diabetes Care

Volumn 27, Issue 7, 2004, Pages 1647-1653

  Charbonnel, Bernard ^a   Dormandy, John ^b   Erdmann, Erland ^c   Massi Benedetti, Massimo ^d   Skene, Allan ^e  

^a Clinique d'Endocrinologie Hotel Dieu CHU de Nantes   (France)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF PERUGIA   (Italy)

^e Nottingham Clinical Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; INSULIN; LOOP DIURETIC AGENT; METFORMIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; POTASSIUM SPARING DIURETIC AGENT; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC DIET; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SMOKING; STROKE;

ADULT; CARDIOVASCULAR DISEASES; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PATIENT SELECTION; THIAZOLIDINEDIONES;

EID: 3042714528     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.7.1647     Document Type: Article

References (61)

1. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 (Suppl. 5): S7-S85, 1997
2. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
3. Williams G, Pickup JC: Macrovascular disease in Diabetes. In Handbook of Diabetes. 2nd ed. Williams G, Pickup JC, Eds. Oxford, U.K., Blackwell Science, 1999, p. 151-158
4. Schernthaner G: Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 31:S3-S13, 1996
5. Haffner SM, Lehto S, Rönnemaa T, Pyöräla K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
7. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
9. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 32:405-412, 2000
10. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
11. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83:2773-2776, 1998
12. Smiley T, Oh P, Shane LG: The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systematic review. Can J Cardiol 17:797-805, 2001
13. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 106:467-472, 2000
14. Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, Tominaga M, Saski H, Ikeda M, Kubota M, Ishada Y, Hozumi T, Baba S, Uehara M, Shichiri M, Kaneko T: Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM: the AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 183:173-183, 1997
15. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 001 Study Group: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605-1611, 2000
16. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
17. Miyazaki Y, Matsuda M, DeFronzo RA: Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25:517-523, 2002
18. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 027 Study Group: Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 22:1395-1409, 2000
19. Kipnes MS, KrosnickA, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 111:10-17, 2001
20. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, the Pioglitazone 014 Study Group: Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 56:251-257, 2002
21. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88:1637-1645, 2003
22. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH, the GLAB study group: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 25:1074-1095, 2003
23. Goke B: Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 1:329-336, 2002
24. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, the QUARTET study group: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147, 2004
25. Lenton S, Schernthaner G, Edwards GC, Lee CE, Tan M, Herz M: The efficacy of pioglitazone compared to metformin in drug-naïve patients with type 2 diabetes (Abstract). Diabetologia 46 (Suppl. 2):A287, 2003
26. Moules I, Maher LJ, Edwards GC, Lee CEF, Urquhart R, Johns D, Tan MH: A comparison of the effects of pioglitazone and gliclazide on metabolic control in drug-naïve patients with type 2 diabetes (Abstract). Diabetes Metab 29:A2296, 2003
27. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G: Long-term combination therapy with metformin plus pioglitazone for type 2 diabetes: a randomised, comparative study. Diabetes Metab Rev. In press
28. Diamant M, Heine RJ: Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63:1373-1405, 2003
29. Groop L: Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 113:3-13, 2000
30. Efrat S: β-Cell expansion for therapeutic compensation of insulin resistance in type 2 diabetes. Int J Exp Diabesity Res 4:1-5, 2003
31. Ovalle F, Bell DSH: Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 4:56-59, 2002
32. Prigeon RL, Kahn SE, Porte Jr. D: Effect of troglitazone on β cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823, 1998
33. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
34. Bell DSH: β-Cell rejuvenation with thiazolidinediones. Am J Med 115 (Suppl. 8A):20S-23S, 2003
35. Uwaifo GI, Ratner RE: The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med 115 (Suppl. 8A): 12S-19S, 2003
36. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
37. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki T, Demura H, Zardi L: Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145:333-340, 1999
38. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146:PE5, 2003
39. Brown V: Detection and management of lipid disorders in diabetes. Diabetes Care 19 (Suppl 1):S96-S102, 1996
40. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 91:831-837, 1995
41. Nakamura TJ, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 14:250-254, 2000
42. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H: Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50:1193-1196, 2001
43. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed M: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17:7-12, 2003
44. Lyon CJ, Hsueh WA: Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115 (Suppl. 8A):62S-68S, 2003
45. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, Mizuno K, Fujita T, Tsukamoto K, Watanabe T: Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 10:431-435, 1999
46. Hsueh WA, Law RE: PPARγ and atherosclerosis: effects on cell growth and movement. Artetioscler Thromb Vasc Biol 21:1891-1895, 2001
47. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83:1097-1103, 1998
48. Peuler JD, Phare SM, Iannucci AR, Hodorek MJ: Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 9:188-192, 1996
49. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905, 1996
50. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820, 1998
51. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region: A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med 14:611-621, 1997
52. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 6:410-418, 1999
53. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
54. American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; The American Heart Association: Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation 100:1132-1133, 1999
55. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO: Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT: Multiple Risk Factor Intervention Trial. Am Heart J 112:825-836, 1986
56. Plavix Clopidigrol prescribing information [article online]. Available from www. sanofi-synthelabous.com/products/pi. Accessed 17 January 2004
57. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
58. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R, Systolic Hypertension in Europe Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684, 1999
59. Fox R: Statins: the new aspirin? (Abstract). Circulation 104:E9051-E9052, 2001
60. Ambrosioni E, Borghi C, Magnani B, the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332:80-85, 1995
61. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and anti-hypertensive therapy as risk factors for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. N Engl J Med 342:905-912, 2000